Compound mutations had more pronounced hypoglycemia and hyperinsulinemia than FOXA2 mutations alone, suggesting that FOXA2 appears to be a more potent regulator than FOXA1 (44). The gene discussed is FOXA2; the disease is hyperinsulinism.